Endothelial-to-mesenchymal transition drives atherosclerosis progression

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4514-4528

  Chen, Pei Yu ^a   Qin, Lingfeng ^a   Baeyens, Nicolas ^a   Li, Guangxin ^a   Afolabi, Titilayo ^a   Budatha, Madhusudhan ^a   Tellides, George ^a   Schwartz, Martin A ^a   Simons, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; NOTCH3 RECEPTOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 2; VIMENTIN; APOLIPOPROTEIN E; FGFR1 PROTEIN, HUMAN; FGFR1 PROTEIN, MOUSE; FRS2 PROTEIN, HUMAN; FRS2ALPHA PROTEIN, MOUSE; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DISRUPTION; CELL TRANSFORMATION; CLINICAL ARTICLE; DISEASE COURSE; ENDOTHELIAL MESENCHYMAL TRANSITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LEFT CORONARY ARTERY; LIPID DIET; NEOINTIMA; OSCILLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SHEAR STRESS; UPREGULATION; ANIMAL; CORONARY ARTERY DISEASE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOLIPOPROTEINS E; CORONARY ARTERY DISEASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 84948808417     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82719     Document Type: Article

References (38)

1. Conway DE, Schwartz MA. Flow-dependent cel lular mechanotransduction in atherosclerosis. J Cell Sci. 2013;126(pt 22):5101-5109.
2. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol. 2009;10(1):53-62.
3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325.
4. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092-1104.
5. Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13-22.
6. Zeisberg EM, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952-961.
7. Maddaluno L, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature. 2013;498(7455):492-496.
8. Kitao A, et al. Endothelial to mesenchymal transition via transforming growth factor-β1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol. 2009;175(2):616-626.
9. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074-1080.
10. Chen PY, et al. FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2012;2(6):1684-1696.
11. Cooley BC, et al. TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med. 2014;6(227):227ra34.
12. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16(12):1400-1406.
13. van Meeteren LA, ten Dijke P. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res. 2012;347(1):177-186.
14. Chen PY, Qin L, Tellides G, Simons M. Fibro-blast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium. Sci Signal. 2014;7(344):ra90.
15. Ten Dijke P, Egorova AD, Goumans MJ, Poel-mann RE, Hierck BP. TGF-β signaling in endothelial-to-mesenchymal transition: the role of shear stress and primary cilia. Sci Signal. 2012;5(212):pt2.
16. Pitulescu ME, Schmidt I, Benedito R, Adams RH. Inducible gene targeting in the neonatal vascula-ture and analysis of retinal angiogenesis in mice. Nat Protoc. 2010;5(9):1518-1534.
17. Feaver RE, Gelfand BD, Wang C, Schwartz MA, Blackman BR. Atheroprone hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation. Circ Res. 2010;106(11):1703-1711.
18. Rohwedder I, et al. Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Mol Med. 2012;4(7):564-576.
19. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011;8(6):348-358.
20. Libby P. Inflammation in atherosclerosis. Arterio-scler Thromb Vasc Biol. 2012;32(9):2045-2051.
21. Li X, Deroide N, Mallat Z. The role of the inflam-masome in cardiovascular diseases. J Mol Med (Berl). 2014;92(4):307-319.
22. Gelfand BD, et al. Hemodynamic activation of β-catenin and T-cell-specific transcription factor signaling in vascular endothelium regulates fibronectin expression. Ar terioscler Thromb Vasc Biol. 2011;31(7):1625-1633.
23. Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21(5):962-968.
24. Scanlon CS, Van Tubergen EA, Inglehart RC, D'Silva NJ. Biomarkers of epithelial-mesenchy-mal transition in squamous cell carcinoma. J Dent Res. 2013;92(2):114-121.
25. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004;104(1):11-18.
26. Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361.
27. Stoger JL, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461-468.
28. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99(11):2752-2761.
29. Tellides G, et al. Interferon-γ elicits arterio-sclerosis in the absence of leukocytes. Nature. 2000;403(6766):207-211.
30. -/-mice. J Interferon Cytokine Res. 2002;22(6):661-670.
31. Everett BM, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of athero-thrombosis. Am Heart J. 2013;166(2):199-207.e15.
32. Lutgens E, et al. Transforming growth factor-p mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002;22(6):975-982.
33. Mallat Z, Tedgui A. The role of transforming growth factor p in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol. 2002;13(5):523-529.
34. Toma I, McCaffrey TA. Transforming growth factor-p and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347(1):155-175.
35. Baeyens N, et al. Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling. Proc Natl Acad Sci USA. 2014;111(48):17308-17313.
36. Lin Y, Zhang J, Zhang Y, Wang F. Generation of an Frs2a conditional null allele. Genesis. 2007;45(9):554-559.
37. Huang Q, et al. AIP1 suppresses atherosclerosis by limiting hyperlipidemia-induced inflammation and vascular endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33(4):795-804.
38. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275.